Clinical

Data from the EMPOWER-Lung 1 trial of cemiplimab (Libtayo) monotherapy vs chemotherapy show why the fully-human monoclonal antibody could become a new treatment option for non–small cell lung cancer (NSCLC).

Patients of South Asian origins who have psoriatic arthritis have a worse clinical phenotype and worse disease impact than patients of North European origins, according to research published in Rheumatology.

Relapse at an older age can significantly contribute to a worsening of multiple sclerosis (MS), explained Burcu Zeyda, MD, assistant professor of neurology, assistant professor of radiology, at Mayo Clinic.

In individuals with type 2 diabetes with no previous insulin treatment, once-weekly injections of insulin icodec resulted in glucose-lowering efficacy and a safety profile similar to individuals who took once-daily insulin glargine U100.

FDA will review the first chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of multiple myeloma (MM) in adults who have not responded or have relapsed after at least 3 other therapies.

The KRAS mutation occurs in 13% of non–small cell lung cancers (NSCLC) and leads to worse outcomes in NSCLC.

A new analysis of ADAURA data shows osimertinib cuts the risk of brain metastases or death by 82% compared with placebo in certain early-stage patients with NSCLC.

Both neurofibromatosis type 1 (NF1) and Tuberous Sclerosis Complex (TSC) share similar types of manifestations; researchers hypothesized that the tool would be useful for NF1 in addition to TSC.

The findings have implications for patient self-management of their chronic disease, and clinicians should screen for worsened cognitive function, the researchers wrote.

The research spotlights the diverse landscape of pediatric cancer types harboring 2 types of genomic alterations.

Kidney cancer rose at least 3% a year during the years studied among adolescents and young adults, according to data from the American Cancer Society.

A new chimeric antigen receptor (CAR) T cell therapy may help curb the problem of frequent relapse in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

The high rate of persistence found in the real-world study indicates dupilumab was well tolerated and patients were satisfied with its effectiveness.

More than half of the patients in this study, with either non–small or small cell lung cancer, experienced changes in their treatment plan during the coronavirus disease 2019 pandemic this spring.

Both patients with early and established psoriatic arthritis (PsA) have similar improvements in general health and mental well-being after treatment with secukinumab.